anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain the subject composition having fresh taste and body feeling without remaining over sweetness, and giving excellent sweetness to a food, a medicinal agent or a quasi-drug, or the like, by including sucralose and gymnemic acid. SOLUTION: This sweetener composition having fresh taste and body feeling and capable of giving excellent sweetness to an orally used product such as a food, a medicinal agent or a quasi-drug without remaining over sweetness as a defect of previous strong sweeteners is obtained by including 0.00001-1 pt.wt. of gymnemic acid per 1 pt.wt. of sucralose. As food products suitable for using this sweetening composition as a sweetener, e.g. a drink such as a carbonated beverage, a fruit drink, coffee, a soft drink, a milk beverage or a tea-based drink, and a dessert such as a mousse, and a confectioneries such as chewing gum and candy is exemplified.
FIELD: medicine; veterinary.SUBSTANCE: invention relates to medicine and veterinary medicine, namely to pharmaceutical compositions used in the treatment of extensive purulent-necrotic post-traumatic, postoperative wounds, extensive burns, as well as wounds after the surgical treatment of acute purulent skin and soft tissue diseases (abscessed boils, carbuncles, mastitis, hydradenitis, erysipelas, etc.), in the treatment of patients with extensive atherosclerotic and venous trophic ulcers, with diabetic foot syndrome, complicated by an infectious process caused by highly resistant gram-positive and gram-negative aerobic and anaerobic microorganisms, fungi resistant to the vast majority of antimicrobial and antifungal drugs. First option is a composition containing fluoroquinolones, more active than ofloxazole, in combination with appropriate target supplements that extend its spectrum of action. Second option is the composition of ofloxacin in combination with the corresponding target additives, expanding the range of its action. Third option is the composition of ofloxacin with a stimulator of the reparative process and an anesthetic in combination with appropriate target additives. Proposed compositions based on fluoroquinolones with the above target additives destroy both gram-positive and gram-negative microorganisms, including resistant to antibiotics, as well as fungi and protozoa.EFFECT: proposed fluoroquinolone-based compositions with the above targeted additives have a high therapeutic activity, improve usability, reduce the consumption of the active substance, help clean wounds from purulent-necrotic masses, give an anesthetic effect, further stimulate reparative processes in the wound, improve microcirculation, reduce secondary necrosis of tissues around the wound, reduce the likelihood of occurrence of strains resistant to the antimicrobial complex of the composition, have a local immunomodulatory effect.30 cl, 61 ex, 2 tbl
Patients in arm A are treated with 3 cycles RVd + i.v. isatuximab, followed by a standard intensification and autologous stem cell transplantation.
Dutasteride is an inhibitor of the 5 alpha reductase type I and type II enzymes that convert testosterone to DHT, the male hormone that leads to benign prostate growth and drives malignant growth. Dutasteride has been shown to significantly decrease intraprostatic DHT in men with localized prostate cancer, and additionally cause apoptosis and regression of some prostate cancers \[Andriole, 2004a; Andriole, 2004b\]. Furthermore, reduction in tumor volume has also been demonstrated in human prostate tissue \[Iczkowski, 2004\]. Dutasteride is currently indicated to treat symptomatic BPH in men with enlarged prostates, but is also being studied to reduce the risk of prostate cancer in men at risk (elevated PSA and previous negative biopsy). Dutasteride is clinically useful at improving lower urinary tract symptoms (LUTS) in men with clinically-localized prostate cancer and voiding difficulty being treated with single-dose goserelin, TUIP, and interval SI. \[Mitcheson, personal observation\].
FIELD: food industry, microbiology. SUBSTANCE: invention relates to production of baking yeast enriched with trace elements. Method of production of iodinated yeast involves addition of the pressed yeast preliminary enriched with iodine in yeast cells as yeast substrate that is highly enriched with iodine to yeast milk in finishing stage of production of yeast. Baking yeast obtained by this method presents the technically pure culture of yeast saccharomycetes fungi that have organic bound iodine in the form of loaded cells distributed by yeast mass. Iodine content in yeast is 0.0008-0.0036 wt. -% by dry matter of yeast biomass. Invention can be used for prophylaxis of states associated with iodine deficiency. EFFECT: improved method of production, valuable curative properties of yeast. 5 cl
The no training group will engage in no training over the course of the pilot study, but will still participate in baseline, 5 week, 10 . This will allow us to determine if changes in the outcome and assessment variables are due to the working memory training or progression in the disease itself.
A vaccine composition comprises an antigen and a promiscuous T-cell epitope (PTCE) of 11-20 amino acids. The PTCE is preferably derived from measles virus protein F, tetanus toxin, Anaplasma marginale, Plasmodium falciparum circumsporozoite protein, influenza haemagglutinin or PADRE. The antigen may be derived from, for example, a protozoan antigen, a fish virus pathogen or a bird pathogen. In particular, vaccine compositions are provided against the avian pathogens including Clostridium perfringens, infectious bursal disease virus (IBDV), infectious bronchitis virus (IBV) and the protozoan pathogen Eimeria, and the fish virus infectious pancreatic necrosis virus (IPNV). Compositions are also provided comprising two or more PTCEs, where the epitopes are joined together by a linker; and a composition comprising a B cell epitope derived from Infectious Bronchitis Virus (IBV), and a T-cell epitope derived from IBV. Methods of vaccinating an animal are provided by administering a PTCE and an antigen, wherein the animal is in ovo or pre-immunocompetent.
The portable device for extracting a plant compound contained in a plant material using water vapor (1), comprises a unit for producing water vapor including a removable water reservoir (2) and a heating unit (4), an extraction chamber connected tightly to the reservoir to contain the plant material having an inlet of steam produced by the production of steam and an outlet of steam and the plant compound produced by the chamber, and a unit for cooling and distilling water vapor obtained from the extraction chamber for obtaining a distillate containing the plant compound. The portable device for extracting a plant compound contained in a plant material using water vapor (1), comprises a unit for producing water vapor including a removable water reservoir (2) and a heating unit (4), an extraction chamber connected tightly to the reservoir to contain the plant material having an inlet of steam produced by the production of steam and an outlet of steam and the plant compound produced by the chamber, and a unit for cooling and distilling water vapor obtained from the extraction chamber for obtaining a distillate containing the plant compound, and an extraction unit by exchange of liposoluble substances contained in the distillate with an oily phase constituting a base oil for massage. The extraction unit includes a container to contain the base oil for massage, a first collection unit of oily phase forming massage oil constituted by the base oil enriched with fat-soluble substances of the distillate and second collection unit of an aqueous phase consisting of aqueous phase of the distillate passed through the oily phase. The extraction chamber is connected with a cartridge containing the plant material, and comprises a unit for perforating a cartridge and a unit for ejecting a cartridge. A venting unit is arranged to evacuate a part of the steam and essential oils produced by the device in the air. An actuating unit is arranged for optionally deactivating the cooling and distilling units. A unit is arranged for detecting information relating to plant material contained in a cartridge or type of plant material contained in the cartridge, where the information is carried by the cartridge or integrated in the cartridge. A unit is arranged for automatic adjustment of an operating parameter of the device or mode of operation based on the information related to the plant material or type of plant material detected by the detection unit. The detection unit comprises a unit for optical detection of a bar code, a unit for detecting a radio frequency, a unit for detecting a color, and a unit for detecting a shape. The container of the separating unit has ampoule shape. An independent claim is included for single use cartridge cooperating with an extraction device.
In the neuromobilization stretching group; The subjects were brought to shoulder depression and 90 degrees of abduction while the dominant side forearms were supination. In this position, median nerve stretching was performed by extending the participant's head to the opposite side while flexing the wrist and finger. After waiting for 30 seconds in this position, the wrist and head were moved to the neutral position and the participants relaxed.
Communicating hydrocephalus secondary to intraventricular hemorrhage is a serious neurological disorder with the main clinical manifestations of ventricular dilatation, gait disturbance, cognitive dysfunction, and urinary incontinence. At present, the sole treatment option for these patients is cerebrospinal fluid shunting. However, complications resulting from this therapy have necessitated multiple surgeries for some patients, which has a significant impact on their quality of life and financial resources. However, recent studies have identified the PI3K-AKT-mTOR pathway as a key contributor to the sequelae of hemorrhagic hydrocephalus. Furthermore, these studies demonstrated that rapamycin, an inhibitor of the PI3K-AKT-mTOR pathway, inhibited cerebrospinal fluid secretion and ventricular dilation in an animal model of hemorrhagic hydrocephalus sequelae. In light of these findings, we propose a prospective, multicenter, open-label clinical trial to evaluate the efficacy and safety of rapamycin in the treatment of communicating hydrocephalus secondary to intraventricular hemorrhage.

The study design was that of a prospective, multicenter, open-label clinical trial. All patients were administered sirolimus (rapamycin) in a dosage of 0.5 mg per capsule. The capsules were provided by the North China Pharmaceutical Company and were stored at room temperature. The treatment course was four weeks, with a dosage of 1.5 mg orally per day. Efficacy and adverse effects were assessed at two weeks, four weeks, the end of treatment, and 12 weeks after the end of treatment, respectively.
The present invention relates to regulation and control of cellular processes by transmembrane protein tyrosine phosphatases, and to ligands that agonize or antagonize tyrosine phosphorylation mediated by such tyrosine phosphatases. This invention further relates to diagnosis and therapy based on the activity of such ligands. In particular, the invention provides a novel transmembrane protein tyrosine phosphatase- lambda  (PTP lambda ), nucleic acids encoding the same, antibodies to the PTP lambda , and methods for identifying ligands to the PTP lambda  of the invention. A specific Example describes the isolation and characterization of the first chicken transmembrane PTP, called ChPTP lambda . It has a unique extracellular domain containing a Ser/Thr/Pro-rich region, spectrin-like repeats, a fibronectin III domain, and an alternatively spliced N-terminus. The expression of ChPTP lambda  in various tissues and cells was also examined. ChPTP lambda  was shown to have a tyrosine-specific phosphatase activity, and the basic characteristics of this enzyme were studied.
A system for delivering a fluid to a patient includes a remote controller and an infusion pump. The infusion pump includes a dispenser for dispensing the fluid. An RF telemetry portion is configured to receive an RF data signal from the remote controller. A main processing portion is configured to process the RF data signal received by the RF telemetry portion, and control the dispenser in accordance with the RF data signal received by the RF telemetry portion. An interlock processing portion is configured to process the RF data signal received by the RF telemetry portion, and control the dispenser in accordance with the RF data signal received by the RF telemetry portion. The RF telemetry portion and at least one of the processing portions are incorporated into a single microchip.
A randomized, crossover study design is used with 2 intervention days and a 6-day washout period, to evaluate the effects of early and late fasting on postprandial glucose responses in healthy adults. Randomization was performed by the Fudan staff with a block size of 2 using a balanced design using computer-executed software. The primary endpoint is the fasting and postprandial blood glucose, insulin, and continuous glucose monitoring after fasting. Secondary endpoints include postprandial blood lipids, clock gene expressions in peripheral blood cells, and non-targeted postprandial plasma metabolome. The 2 intervention days include a no-breakfast day and a no-dinner day. The diets before, during, and after the intervention day was designed according to Dietary Guidelines for Chinese Residents (2022), and the energy distribution of three meals is 1:1:1, with the energy percentage of carbohydrate, protein, and fat being 55%, 15%, and 30%, respectively. The time of breakfast, lunch, and dinner is 7.30 a.m., 1.00 p.m., and 8.00 p.m., respectively. All participants are instructed to follow their natural dietary plans in the wash-out period, and the food intakes and sleep circle were recorded by a modified food frequency questionnaire (FFQ).
BACKGROUND AND AIMS: Defecation Disorders (DD) are a frequent cause of refractory chronic constipation. DD diagnosis requires anorectal physiology testing. Our aim was to evaluate the accuracy and Odds Ratio (OR) of a straining question (SQ) and a digital rectal examination (DRE) augmented by abdomen palpation on predicting a DD diagnosis in refractory CC patients.
METHODS: Two hundred and thirty-eight constipated patients were enrolled. Patients underwent SQ, augmented DRE and balloon evacuation test before entering the study and after a 30-day fiber/laxative trial. All patients underwent anorectal manometry. OR and accuracy were calculated for SQ and augmented DRE for both dyssynergic defecation and inadequate propulsion.
RESULTS: "Anal Muscles" response was associated to both dyssynergic defecation and inadequate propulsion, with an OR of 13.6 and 5.85 and an accuracy of 78.5% and 66.4%, respectively. "Failed anal relaxation" on augmented DRE was associated with dyssynergic defecation, with an OR of 21.4 and an accuracy of 73.1%. "Failed abdominal contraction" on augmented DRE was associated with inadequate propulsion with an OR >100 and an accuracy of 97.1%.
CONCLUSIONS: Our data support screening constipated patients for DD by SQ and augmented DRE to improve management and appropriateness of referral to biofeedback.
Techniques are provided for managing sharing of data for users. An authorization is received from a user to share user data between a plurality of organizations. The user data is stored in one or more isolated databases. A medical records data management system generates a shared database comprising content including the user data to provide access to the user data to the plurality of organizations. The shared database comprises a data structure for associating the user data an origin of the user data. When revocation by a user to withdraw authorization to share data between the plurality of organizations is received, the content of the shared database is resolved into the one or more isolated databases, and the content is assigned to the isolated database based upon the origin of the user data in the data structure. Access is closed to the shared database.
PCT No. PCT/US95/01827 Sec. 371 Date Oct. 16, 1997 Sec. 102(e) Date Oct. 16, 1997 PCT Filed Jan. 20, 1995 PCT Pub. No. WO96/22360 PCT Pub. Date Jul. 25, 1996A human prostatic specific reductase polypeptide and polynucleotides encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polynucleotides as a diagnostic marker for prostate cancer and as an agent to determine if the prostate cancer has metastasized. Also disclosed are antibodies specific to the prostatic specific reductase polypeptide which may be used to target prostate cancer cells and be used as part of a prostate cancer vaccine. Methods of screening for agonists and antagonists for the polypeptide and therapeutic uses of the antagonists are also dislcosed.
PURPOSE: A composition containing Schizandra chinensis Baillon. Ethyl acetate fraction or woweizisu C is provided to suppress adipocyte differentiation, to lipid accumulation, and to prevent or treat obesity. CONSTITUTION: A pharmaceutical composition for preventing or treating obesity contains Schizandra chinensis Baillon. ethyl acetate fraction as an active ingredient. A pharmaceutical composition for preventing or treating obesity contains wuweizisu C of chemical formula 1 as an active ingredient. Woweizisu C is isolated from the fraction. A food composition for preventing or treating obeisty contains the fraction and woweizisu as an active ingredient. A method for preparing the fraction or woweizisu C comprises: a step of washing Schizandra chinensis Baillon. with water, drying and pulverizing; a step of adding solvent to the Schizandra chinensis Baillon. powder and dipping to prepare Schizandra chinensis Baillon. extract; a step of filtering and concentrating the extract; a step of suspending the extract concentrate in distilled water; a step of fractioning with hexane, chloroform, ethyl acetate, butanol, and water.
Compartment syndrome of the thigh and a pseudoaneurysm of the arteria profunda femoris are rare entities that usually occur independently. Untreated, both can lead to life-threatening complications making prompt diagnosis and management mandatory. The diagnosis of an acute compartment syndrome can be suspected clinically, and subsequently needs to be confirmed by intra-compartmental pressure measurement. Treatment should be done by urgent fasciotomy within 6 hours. A pseudoaneurysm can also be suspected clinically. Various imaging modalities exist to confirm the diagnosis, with duplex ultrasound being the diagnostic test of choice. Treatment is depending on the importance of clinical symptoms and on the size of the pseudoaneurysm. We present the first case in which an acute compartment syndrome of the thigh was complicated by a pseudoaneurysm of the arteria profunda femoris. The pseudoaneurysm was subsequently complicated by hemorrhage and infection.
Diabetic cognitive impairment is a common complication in type 2 diabetes. Berberine (BBR) is an isoquinoline alkaloid that has been shown to have neuroprotective effects against diabetes. This study aimed to investigate the effect of BBR on the gray and white matter of the brain by using magnetic resonance imaging (MRI) and to explore the underlying mechanisms. The study used diabetic db/db mice and administered BBR (50 and 100 mg/kg) intragastrically for twelve weeks. Morris water maze was applied to examine cognitive function. T2-weighted imaging (T2WI) was performed to assess brain atrophy, and diffusion tensor imaging (DTI) combined with fiber tracking was conducted to monitor the structural integrity of the white matter, followed by histological immunostaining. Furthermore, the protein expressions of the phosphatidylinositol 3-kinase (PI3K)/ protein kinase B (AKT)/ glycogen synthase kinase-3β (GSK-3β) were detected. The results revealed that BBR significantly improved the spatial learning and memory of the db/db mice. T2WI exhibited ameliorated brain atrophy in the BBR-treated db/db mice, as evidenced by reduced ventricular volume accompanied by increased hippocampal volumes. DTI combined with fiber tracking revealed that BBR increased FA, fiber density and length in the corpus callosum/external capsule of the db/db mice. These imaging findings were confirmed by histological immunostaining. Notably, BBR significantly enhanced the protein levels of phosphorylated AKT at Ser473 and GSK-3β at Ser9. Collectively, this study demonstrated that BBR significantly improved the cognitive function of the diabetic db/db mice through ameliorating brain atrophy and promoting white matter reorganization via AKT/GSK-3β pathway.
PROBLEM TO BE SOLVED: To obtain a makeup base for cosmetics having excellent durability of cosmetic effect low in stretched feeling of or pressing feeling to the skin by blending silicone paste therewith. SOLUTION: This makeup base for cosmetics contains 1-100wt.%, preferably 30-100wt.% of silicone paste obtained by blending or crushing a silicone elastomer with a silicone oil, and platy powder, especially platy barium sulfate, talc, mica, sericite, kaolin, etc., when occasion demands. The silicone elastomer is resin powder having 0.1-20μm average primary particle diameter and dimethylpolysiloxane, etc., having 1-1,000cst viscosity at a normal temperature is preferably used as the silicone oil. As for components other than above components, those used in cosmetics can suitably be mixed in the silicone paste. The objective makeup base for cosmetics can be used also as a filter color having a makeup base effect by coloring with powder or a pigment, etc.  Especially, the makeup base is effective for improving durability of a cosmetic such as a foundation, face powder, eye shadow and rouge.